Delafloxacin
Encyclopedia
Delafloxacin is a fluoroquinolone antibiotic
being developed by Rib-X Pharmaceuticals
, Inc.
It is more active (lower MIC90
) than other quinolones against Gram-positive bacteria such as MRSA.
Phase II clinical trials have been completed, including a trial with tigecycline
as a comparator
Antibiotic
An antibacterial is a compound or substance that kills or slows down the growth of bacteria.The term is often used synonymously with the term antibiotic; today, however, with increased knowledge of the causative agents of various infectious diseases, antibiotic has come to denote a broader range of...
being developed by Rib-X Pharmaceuticals
Rib-X Pharmaceuticals
Rib-X Pharmaceuticals, founded in 2000, is a privately-held biopharmaceutical firm that focuses on the design and development of novel broad-spectrum antibiotics for the treatment of antibiotic-resistant infections in hospital and community settings. The company is located in New Haven, Connecticut...
, Inc.
It is more active (lower MIC90
Minimum inhibitory concentration
In microbiology, minimum inhibitory concentration is the lowest concentration of an antimicrobial that will inhibit the visible growth of a microorganism after overnight incubation. Minimum inhibitory concentrations are important in diagnostic laboratories to confirm resistance of microorganisms...
) than other quinolones against Gram-positive bacteria such as MRSA.
Phase II clinical trials have been completed, including a trial with tigecycline
Tigecycline
Tigecycline is a glycylcycline antibiotic developed by Francis Tally and marketed by Wyeth under the brand name Tygacil. It was given a U.S. Food and Drug Administration fast-track approval and was approved on June 17, 2005...
as a comparator